SymBio Pharmaceuticals

TYO: 4582

JPY15676.2m market cap

JPY460 last close

SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio’s branded formulation of bendamustine HCl. Rigosertib was in-licensed from Onconova.

Investment summary

SymBio will be presenting data at the European Society of Hematology (EHA) meeting from its pivotal study in Japan of Treakisym (bendamustine) in combination with rituximab for the treatment of diffuse large B-cell lymphoma (DLBCL). The 38-patient, single-arm study showed a 76% overall response rate (ORR), with 47% of patients achieving a complete response (CR). This gives us a high degree of confidence in the label expansion for this population submitted in May 2020.

Y/E Dec
Revenue (¥m)
PBT (¥m)
EPS (fd) (¥)
P/E (x)
P/CF (x)
2018A 3836.0 (2621.0) (2749.0) (166.0) N/A N/A
2019A 2838.0 (4264.0) (4377.0) (189.0) N/A N/A
2020E 3433.0 (5000.0) (5078.0) (170.0) N/A N/A
2021E 9159.0 1034.0 962.0 50.0 920.0 14.0
Industry outlook

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operational leverage.

Last updated on 28/05/2020
Share price graph
Balance sheet
Forecast net cash (¥m) 193
Forecast gearing ratio (%) N/A
Price performance
Actual 24.3 2.7 (35.8)
Relative* 14.2 (1.7) (36.8)
52-week high/low ¥791.0/¥264.0
*% relative to local index
Key management
Fuminori Yoshida Representative Director, President & CEO
Kenji Murata Corporate Officer

Content on SymBio Pharmaceuticals